About: A Novel Vaccine Using Nanoparticle Platform to Present Immunogenic M2e against Avian Influenza Infection

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: A Novel Vaccine Using Nanoparticle Platform to Present Immunogenic M2e against Avian Influenza Infection Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	A Novel Vaccine Using Nanoparticle Platform to Present Immunogenic M2e against Avian Influenza Infection
Creator	Burkhard, Peter Mittelholzer, Christian Neef, Tobias Babapoor, Sankhiros Garmendia, Antonio Girshick, Theodore Shang, Hongwei Khan, Mazhar Zhirnov, Oleg
topic	covid:c66d7cf6243be684d42751e19f4f9c27ca8a1f3b#this
Source	PMC
abstract	Using peptide nanoparticle technology, we have designed two novel vaccine constructs representing M2e in monomeric (Mono-M2e) and tetrameric (Tetra-M2e) forms. Groups of specific pathogen free (SPF) chickens were immunized intramuscularly with Mono-M2e or Tetra-M2e with and without an adjuvant. Two weeks after the second boost, chickens were challenged with 107.2 EID50 of H5N2 low pathogenicity avian influenza (LPAI) virus. M2e-specific antibody responses to each of the vaccine constructs were tested by ELISA. Vaccinated chickens exhibited increased M2e-specific IgG responses for each of the constructs as compared to a non-vaccinated group. However, the vaccine construct Tetra-M2e elicited a significantly higher antibody response when it was used with an adjuvant. On the other hand, virus neutralization assays indicated that immune protection is not by way of neutralizing antibodies. The level of protection was evaluated using quantitative real time PCR at 4, 6, and 8 days post-challenge with H5N2 LPAI by measuring virus shedding from trachea and cloaca. The Tetra-M2e with adjuvant offered statistically significant (P < 0.05) protection against subtype H5N2 LPAI by reduction of the AI virus shedding. The results suggest that the self-assembling polypeptide nanoparticle shows promise as a potential platform for a development of a vaccine against AI.
has issue date	2012-01-12(xsd:dateTime)
bibo:doi	10.1155/2011/126794
bibo:pmid	23074652
has license	cc-by
sha1sum (hex)	c66d7cf6243be684d42751e19f4f9c27ca8a1f3b
schema:url	https://doi.org/10.1155/2011/126794
resource representing a document's title	A Novel Vaccine Using Nanoparticle Platform to Present Immunogenic M2e against Avian Influenza Infection
has PubMed Central identifier	PMC3447297
has PubMed identifier	23074652
schema:publication	Influenza Res Treat
resource representing a document's body	covid:c66d7cf6243be684d42751e19f4f9c27ca8a1f3b#body_text
is http://vocab.deri.ie/void#inDataset of	https://covidontheweb.inria.fr:4443/about/id/http/ns.inria.fr/covid19/c66d7cf6243be684d42751e19f4f9c27ca8a1f3b
is schema:about of	named entity 'IMMUNOGENIC' named entity 'monomeric' named entity 'group' named entity 'vaccine' named entity 'vaccine' named entity 'assays' named entity 'virus shedding' named entity 'constructs' named entity 'weeks' named entity 'Vaccine' named entity 'PLATFORM' named entity 'LOW' named entity 'MEASURING' named entity 'USING' named entity 'INDICATED' named entity 'PROTECTION' named entity 'EVALUATED' named entity 'TESTED' named entity 'VACCINATED' named entity 'INCREASED' named entity 'GROUPS' named entity 'FREE' named entity 'SECOND' named entity 'IMMUNIZED' named entity 'DAYS' named entity 'POLYPEPTIDE' named entity 'USED' named entity 'M2E' named entity 'TWO WEEKS' named entity 'QUANTITATIVE REAL TIME PCR' named entity 'DEVELOPMENT' named entity 'M2E' named entity 'NOVEL' named entity 'GROUP' named entity 'PEPTIDE' named entity 'NANOPARTICLE' named entity '107' named entity 'NON-' named entity 'NANOPARTICLE' named entity 'PRESENT' named entity 'INFLUENZA INFECTION' named entity 'PATHOGENICITY' named entity 'STATISTICALLY SIGNIFICANT' named entity 'OFFERED' named entity 'PLATFORM' named entity 'CLOACA' named entity 'REDUCTION' named entity 'SUBTYPE' named entity 'HIGHER' named entity 'IMMUNE PROTECTION' named entity 'TRACHEA' named entity 'RESULTS' named entity 'LEVEL' named entity 'CONSTRUCT' named entity 'ADJUVANT' named entity 'POTENTIAL' named entity 'EID50' named entity 'ELISA' named entity '28P' named entity 'TECHNOLOGY' named entity 'TETRA' named entity 'NEUTRALIZING ANTIBODIES' named entity 'VIRUS' named entity 'COMPARED' named entity 'VIRUS NEUTRALIZATION' named entity 'AVIAN INFLUENZA' named entity 'VIRUS SHEDDING' named entity 'VACCINE' named entity 'SPECIFIC ANTIBODY' named entity 'IGG' named entity 'FORMS'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software